Ignite Creation Date:
2025-12-25 @ 3:09 AM
Ignite Modification Date:
2026-01-01 @ 6:36 AM
Study NCT ID:
NCT05013905
Status:
COMPLETED
Last Update Posted:
2025-07-04
First Post:
2021-08-13
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase 2a Safety and Efficacy Open-Label Study of PRA023 in Subjects With Moderately to Severely Active Crohn's Disease
Sponsor:
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-07-28
Start Date Type:
ACTUAL
Primary Completion Date:
2022-09-23
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-05-27
Completion Date Type:
ACTUAL
First Submit Date:
2021-08-13
First Submit QC Date:
None
Study First Post Date:
2021-08-19
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2023-09-11
Results First Submit QC Date:
None
Results First Post Date:
2023-11-01
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-06-26
Last Update Post Date:
2025-07-04
Last Update Post Date Type:
ACTUAL